ArticleExperimental hematology2012
Ex vivo fucosylation improves human cord blood engraftment in NOD-SCID IL-2Rγ(null) mice.
Article in Experimental hematology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 85 citations in OpenAlex.
- Complement fragment 3a priming of umbilical cord blood progenitors: safety profile.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2013Trial
- In vivo DPP-4 inhibition to enhance engraftment of single-unit cord blood transplants in adults with hematological malignancies.Stem cells and development · 2013Trial
- Correlation of infused CD3+CD8+ cells with single-donor dominance after double-unit cord blood transplantation.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2013Trial
- Cord-blood engraftment with ex vivo mesenchymal-cell coculture.The New England journal of medicine · 2012Trial
- Ex Vivo Expansion of Cord Blood Hematopoietic Stem and Progenitor Cells.Methods in molecular biology (Clifton, N.J.) · 2025Article
- Metabolic Glycoengineering: A Promising Strategy to Remodel Microenvironments for Regenerative Therapy.Stem cells international · 2023Review
- Clinical Progress and Preclinical Insights Into Umbilical Cord Blood Transplantation Improvement.Stem cells translational medicine · 2022Review
- Refining the migration and engraftment of short-term and long-term HSCs by enhancing homing-specific adhesion mechanisms.Blood advances · 2022Article
- Mechanistic Basis of ex Vivo Umbilical Cord Blood Stem Progenitor Cell Expansion.Stem cell reviews and reports · 2020Review
- Exploiting metabolic glycoengineering to advance healthcare.Nature reviews. Chemistry · 2019Article
- Current and future perspectives on allogeneic transplantation using ex vivo expansion or manipulation of umbilical cord blood cells.International journal of hematology · 2019Review
- Fucosylation Enhances the Efficacy of Adoptively Transferred Antigen-Specific Cytotoxic T Lymphocytes.Clinical cancer research : an official journal of the American Association for Cancer Research · 2019Article
- Past, present, and future efforts to enhance the efficacy of cord blood hematopoietic cell transplantation.F1000Research · 2019Review
- Migration against the direction of flow is LFA-1-dependent in human hematopoietic stem and progenitor cells.Journal of cell science · 2018Article
- The First Step in Adoptive Cell Immunotherapeutics: Assuring Cell Delivery via Glycoengineering.Frontiers in immunology · 2018Article
- Expression and Characterization of Human β-1, 4-Galactosyltransferase 1 (β4GalT1) Using Silkworm-Baculovirus Expression System.Molecular biotechnology · 2017Article
- Engineering cord blood to improve engraftment after cord blood transplant.Stem cell investigation · 2017Review
- Multiple allogeneic progenitors in combination function as a unit to support early transient hematopoiesis in transplantation.The Journal of experimental medicine · 2016Article
- Optimizing autologous cell grafts to improve stem cell gene therapy.Experimental hematology · 2016Review
- Ex Vivo Expansion or Manipulation of Stem Cells to Improve Outcome of Umbilical Cord Blood Transplantation.Current hematologic malignancy reports · 2016Article
Corrections and comments
- Commented on by
Authors and funding
19 authors at 4 institutions in 1 country.
Funding
Abstract
Delayed engraftment remains a major hurdle after cord blood (CB) transplantation. It may be due, at least in part, to low fucosylation of cell surface molecules important for homing to the bone marrow microenvironment. Because fucosylation of specific cell surface ligands is required before effective interaction with selectins expressed by the bone marrow microvasculature can occur, a simple 30-minute ex vivo incubation of CB hematopoietic progenitor cells with fucosyltransferase-VI and its substrate (GDP-fucose) was performed to increase levels of fucosylation. The physiologic impact of CB hematopoietic progenitor cell hypofucosylation was investigated in vivo in NOD-SCID interleukin (IL)-2Rγ(null) (NSG) mice. By isolating fucosylated and nonfucosylated CD34(+) cells from CB, we showed that only fucosylated CD34(+) cells are responsible for engraftment in NSG mice. In addition, because the proportion of CD34(+) cells that are fucosylated in CB is significantly less than in bone marrow and peripheral blood, we hypothesize that these combined observations might explain, at least in part, the delayed engraftment observed after CB transplantation. Because engraftment appears to be correlated with the fucosylation of CD34(+) cells, we hypothesized that increasing the proportion of CD34(+) cells that are fucosylated would improve CB engraftment. Ex vivo treatment with fucosyltransferase-VI significantly increases the levels of CD34(+) fucosylation and, as hypothesized, this was associated with improved engraftment. Ex vivo fucosylation did not alter the biodistribution of engrafting cells or pattern of long-term, multilineage, multi-tissue engraftment. We propose that ex vivo fucosylation will similarly improve the rate and magnitude of engraftment for CB transplant recipients in a clinical setting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.